Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Novartis's Durcabtagene autoleucel?
Durcabtagene autoleucel is a gene-modified cell therapy commercialized by Novartis, with a leading Phase II program in Relapsed Multiple Myeloma;Refractory...
Durcabtagene autoleucel by Novartis for Relapsed Multiple Myeloma: Likelihood of Approval
Durcabtagene autoleucel is under clinical development by Novartis and currently in Phase II for Relapsed Multiple Myeloma. According to GlobalData,...
Durcabtagene autoleucel by Novartis for Refractory Multiple Myeloma: Likelihood of Approval
Durcabtagene autoleucel is under clinical development by Novartis and currently in Phase II for Refractory Multiple Myeloma. According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Novartis's Durcabtagene autoleucel?
Durcabtagene autoleucel is a gene-modified cell therapy commercialized by Novartis, with a leading Phase II program in Refractory Multiple Myeloma....